Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
Facility Information
This content was archived on June 24, 2013.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
The purpose of this document is to provide clear guidance to the biological drug industry regarding the inclusion of product-specific facility information in drug submissions containing a Quality component (chemistry and manufacturing). This guidance document should be considered in the preparation of all submissions containing a chemistry and manufacturing component which requires facility information, i.e., New Drug Submissions (NDSs), Supplemental New Drug Submissions (S/NDSs) and Biological DIN Applications (DINBs).
In addition, a corresponding guidance document for industry is available regarding the type of submission to file when product-related changes are being made to a facility where an approved drug product is being fabricated.
Please note that Guidance For Industry - Changes in Product-Specific Facility Information replaces the document entitled Bureau of Biologics and Radiopharmaceuticals, Guidance to Industry Product-Specific Facility Information.
- Bureau of Biologics and Radiopharmaceuticals, Guidance to Industry Product-Specific Facility Information [1999-03-10]
